First-Line Treatment Selection and Adverse Event Management in EGFR-Mutated Metastatic NSCLC

Jiaxin (Jason) Niu, MD, and Amanda Edmond, PA-C, open a virtual tumor board on first-line treatment for EGFR-mutated metastatic non–small cell lung cancer (NSCLC).

Jiaxin (Jason) Niu, MD, reviews first-line treatment options for EGFR-mutant metastatic non–small cell lung cancer (NSCLC), noting that osimertinib monotherapy was the preferred first-line therapy based on the FLAURA trial, which began in 2018.